The RITAZAREM trial
Sunday 10 November: 11:00–12:30, Hall B1, Georgia World Congress Center, Atlanta, USA
Presenter: Rona Smith, University of Cambridge, UK
RITAZAREM involves 170 patients with antineutrophil cytoplasmic antibody- associated vasculitis and relapsing disease who on achieving remission at 4 months were randomly assigned to maintenance treatment with rituximab or azathioprine. The follow-up was a minimum of 36 months with the primary outcome being the time to disease relapse.